Assessments on Current Pain Managements in Upper Gastrointestinal Cancer Patients

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Hsu-chih Chien, National Cheng Kung University
ClinicalTrials.gov Identifier:
NCT01718821
First received: October 16, 2012
Last updated: September 11, 2013
Last verified: September 2013

October 16, 2012
September 11, 2013
September 2012
September 2013   (final data collection date for primary outcome measure)
  • Pain, assessed by BPI-SF. [ Time Frame: Assessed at enrolled date (Day 1) ] [ Designated as safety issue: No ]
    Pain intensities of participants would be assessed by BPI-SF at D1.
  • Changes in pain, assessed by BPI-SF. [ Time Frame: Baseline and 1 month. ] [ Designated as safety issue: No ]
    Changes in pain intensities of participants would be assessed by BPI-SF. The changes in pain would be assessed again after 1 month when participants have outpatient visits or during their admission. An expected following duration average of would be 4 weeks.
Same as current
Complete list of historical versions of study NCT01718821 on ClinicalTrials.gov Archive Site
  • Depression, assessed by two stem questions. [ Time Frame: Assessed at enrolled date (Day 1) ] [ Designated as safety issue: No ]
    Depression of participants would be assessed by questionnaires as mentioned at D1.
  • Changes in depression, assessed by two stem questions. [ Time Frame: Baseline and 1 month. ] [ Designated as safety issue: No ]
    Changes in depression status would be assessed by questionnaires as mentioned. The changes would be assessed again after 1 month when participants have outpatient visits or during their admission. An expected following duration average of would be 4 weeks.
  • Quality of life, assessed by EROTC QLQ C30. [ Time Frame: Day 1 ] [ Designated as safety issue: No ]
    Quality of life of participants would be assessed by questionnaires as mentioned at D1.
  • Neuropathic pain, assessed by DN4 questions. [ Time Frame: Day 1 ] [ Designated as safety issue: No ]
    Neuropathic pain of participants would be assessed by questionnaires as mentioned at D1.
  • Changes in quality of life. Quality of life, assessed by EROTC QLQ C30. [ Time Frame: Baseline and 1 month. ] [ Designated as safety issue: No ]
    Changes in quality of life would be assessed by questionnaires as mentioned. The changes would be assessed again after 1 month when participants have outpatient visits or during their admission. An expected following duration average of would be 4 weeks.
  • Changes in neuropathic pain. Neuropathic pain, assessed by DN4 questions. [ Time Frame: Baseline and 1 month. ] [ Designated as safety issue: No ]
    Changes in neuropathic pain would be assessed by questionnaires as mentioned. The changes would be assessed again after 1 month when participants have outpatient visits or during their admission. An expected following duration average of would be 4 weeks.
Same as current
Not Provided
Not Provided
 
Assessments on Current Pain Managements in Upper Gastrointestinal Cancer Patients
Assessments on Current Pain Managements in Upper Gastrointestinal Cancer Patients

Pain is one of the most common symptoms associated with cancer. The approach to pain management compresses routine pain assessments, utilizes both pharmacologic and nonpharmacologic interventions, and requires ongoing reevaluation of the patient. Cancer pain can be well controlled in the vast majority of patients if the algorithms of pain control are systematically applied, carefully monitored, and tailored to the needs of the individual patient.This study is aimed to assess the current pain managements in upper gastrointestinal cancer patients in Taiwan. The effects of neuropathic pain and depression on the enrolled patients would also be assessed.

Not Provided
Observational
Observational Model: Ecologic or Community
Time Perspective: Prospective
Not Provided
Not Provided
Probability Sample

Admitted patients or out patients in National Cheng Kung University Hospital (a medical center)

  • Pain
  • Neuropathic Pain
  • Depression
  • Quality of Life
  • Upper GI Cancer
Not Provided
Advanced upper GI cancer patients
Upper GI cancers include: esophageal cancer, gastric cancer, ampulla vater cancer, pancreatic cancer and cholangiocarcinoma.
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
250
August 2014
September 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • with a diagnose of advanced upper GI cancer based on pathology or imaging studies
  • could report pain intensities and answer questionnaires by him/herself

Exclusion Criteria:

  • with major neurologic or psychiatric diseases
  • could not report pain intensities and answer questionnaires by him/herself
Both
20 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Taiwan
 
NCT01718821
A-ER-101-134
No
Hsu-chih Chien, National Cheng Kung University
National Cheng Kung University
Not Provided
Principal Investigator: Yea-huei Kao Yang Institute of Clinical Pharmacy and Pharmaceutical Science, National Cheng Kung University
National Cheng Kung University
September 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP